Afuco™ Anti-Human CFC1 ADCC Theraputic Antibody (BIIB015), ADCC Enhanced
Product Quick Detail
- Minimum Order
- 1
- Place Of Origin
- USA
- Packaging
- N/A
- Delivery
- 15 Days
Specifications
Anti-CFC1 ADCC Enhanced Antibody (BIIB015) is an ADCC enhanced antibody produced by our Afuco™ platform. BIIB015 is an immunoconjugate created for the treatment of solid tumours and is
currently in Phase I of clinical evaluation. BIIB015 consists of a humanised monoclonal antibody against the Cripto protein carrying a payload, via a hindered disulphide linker, of the maytansinoid
derivative, DM4. BIIB015 shows robust activity with results ranging from>50% tumour inhibition to complete tumour regression. In addition, BIIB015 can be combined with standard of care
chemotherapeutics for enhanced efficacy.
https://www.creativebiolabs.net/Anti-CFC1-ADCC-Enhanced-Antibody-BIIB015-20457.htm
- Country: United States
- Business Type:
- Market:
- Founded Year:2005
- Address:
- Contact:Jerry Carter
